Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• TP53-mutant blood cancers present significant clinical challenges.
• BH3-mimetic drugs induce cancer cell apoptosis by inhibiting BCL-2, but their efficacy is limited in TP53-deficient cancers.
• The precise mechanism by which functional p53 enhances BH3-mimetic drug efficacy remains unclear.

Purpose of the Study:

• To elucidate the role of p53 in mediating the efficacy of BH3-mimetic drugs.
• To identify alternative therapeutic strategies for TP53-mutant blood cancers.
• To investigate the potential of the cGAS/STING pathway as a therapeutic target.

Main Methods:

• Investigated p53 activation following BH3-mimetic treatment.
• Analyzed the role of the p53-dependent feedforward loop in apoptosis.
• Utilized STING agonists in combination with BH3-mimetic drugs in preclinical models.

Main Results:

• p53 is activated post-mitochondrial outer membrane permeabilization, inducing BH3-only proteins and potentiating apoptosis.
• TP53-deficient lymphomas lack this pro-apoptotic feedback loop, contributing to treatment resistance.
• Direct activation of the cGAS/STING pathway promotes p53-independent apoptosis via BH3-only protein upregulation.
• Combination therapy of STING agonists and BH3-mimetics demonstrated potent killing of various TP53-mutant blood cancer cells.

Conclusions:

• A novel p53-dependent feedforward loop amplifies BH3-mimetic-induced apoptosis.
• The cGAS/STING pathway offers a viable therapeutic strategy to overcome p53 defects in blood cancers.
• Combination therapy with STING agonists and BH3-mimetics shows promise for treating TP53-mutant blood cancers.